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Introduction
1 New therapeutic agents are needed for the therapy of rabies encephalitis in humans. Despite 2 initial enthusiasm about therapy with the anesthetic agent ketamine (6), recent experimental (19) 3 and clinical (4) evidence have raised questions about the therapeutic usefulness of this agent in 4 human rabies. A combination of therapeutic agents is a reasonable approach for consideration in 5 rabies as used in other viral infections and other diseases (6). Minocycline is a tetracycline-6 derivative with anti-apoptotic and anti-inflammatory properties, and the drug has been shown to 7 have beneficial effects in a variety of neurological disorders (21). Efficacy of minocycline 8 therapy has also been reported in a variety of experimental models of viral infections in animals, 9
including neuroadapted Sindbis virus infection of mice (2), reovirus infection of neonatal mice 10 (14), and simian immunodeficiency virus infection of pigtailed macaques (23). In this report we 11 evaluate the efficacy of using minocycline therapy in experimental infection of neonatal mice 12 with rabies virus as well as in rabies virus-infected mouse embryonic neurons. We have selected 13 a model using the SAD-D29 strain of rabies virus with peripheral inoculation in neonatal mice 14 (5) , that, with adjustment of the viral dose, produces brain infection with only about a 50% 15 mortality rate and facilitates evaluation of either mild beneficial or detrimental effects of the 16 therapy. Preliminary studies in adult mice with highly virulent rabies virus (challenge virus 17 standand-11) had failed to demonstrate a beneficial effect. We have recently characterized this 18 model and shown an encephalitis with prominent lesions in the brainstem and cerebellum (5) . The SAD-D29 strain (D29) of rabies virus was obtained from Teshome Mebatsion (Intervet 4 International, Boxmeer, The Netherlands) (11) . D29 was generated by substitution of arginine 5 (R333) of the mature rabies virus glycoprotein with aspartic acid (D333) using recombinant 6 rabies virus L16, which contains the authentic sequence of the SAD-B19 vaccine strain (11) . 7
Baby hamster kidney (BHK) cells (C13 clone) grown in Dulbecco's modified Eagle medium 8 (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen Life Technologies, 9
Canada) were used for virus propagation. 10 11
Preparation of primary neuron cultures 12
Primary cultures of mouse cortical and hippocampus neurons were prepared as described 13 previously (1). E17 pregnant CD-1 mice were anesthetized with isoflurane (Baxter Corporation, 14 Canada) and fetuses were immediately removed from the uterus and placed in a petri-dish on ice. 15
Under sterile conditions, the fetuses were separated from the embryonic sacs. The fetal cerebral 16 cortices and hippocampi were collected and digested with trypsin (0.1%) and DNAse I (50 17 µg/mL). The tissues were pooled in sterile Neurobasal medium (Invitrogen Life Technologies, 18 Canada) supplemented with B27 (2%) and penicillin-streptomycin (100 IU/mL), triturated, and 19 filtered through a 37 µm nylon mesh. The filtrate was centrifuged for 10 minutes at 1000 rpm 20 and resuspended in Neurobasal medium at a concentration of 1.0 × 10 4 cells/mL. Cells were then 21 plated onto 24 (1 mL) well plates containing 12-mm round coverslips coated with poly-D-lysine 22
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Determination of viability of infected primary neuron cultures 4
Neurons plated in 24-(1 mL) well plates (1 ×10 4 neurons per well) were infected at a 5 multiplicity of infection of 10 focus-forming units (ffu)/neuron of D29. After viral adsorption for 6 1 hr, the cells were washed once with PBS and fresh Neurobasal medium with or without 7 minocycline (Cat. # M-9511, Sigma-Aldrich, St. Louis, MO) was added immediately with 8 incubation at 37 o C. Media and minocycline were not replenished. At 24, 48, and 72 hr post-9 infection (p.i.) cells were fixed with 4% paraformaldehyde and viability was determined by 10 trypan blue exclusion with phase-contrast microscopy at high power magnification (40× 11 objective). Three separate experiments were performed. Trypan blue exclusion is a cell viability 12 assay based on the ability of the cells to exclude the vital dye trypan blue, and cells in an early 13 stage of apoptosis would be expected to exclude the dye and score as viable cells (10). Non-14 viable neurons failed to exclude the vital dye and showed trypan blue staining in their cytoplasm. 
Clinical observations 10
Mice were evaluated daily for 28 days p.i. for clinical neurological signs, including hunching, 11 limb paresis, and ataxia. Moribund animals were euthanized. Deaths occurring during the first 3 12 days p.i. were excluded because they were likely unrelated to the infection. 13
14

Preparation of tissue sections 15
Mice were anesthetized with isoflurane and perfused with buffered 4% paraformaldehyde 16 between days 3 to 7 p.i., or after they developed clinical rabies and became moribund. Brains 17 were removed and immersion-fixed in the same fixative for 24 h at 4 o C. Coronal tissue sections 18 (6 µm) were prepared after dehydration and embedding in paraffin and stained with cresyl violet 19 for light microscopic examination. 20
21
Assessment of neuronal apoptosis in mouse tissues 22
Neuronal apoptosis was graded in major regional brain areas of minocycline-and vehicle-treated Over 95% of the cells in the cortical and hippocampal cultures expressed the neuronal marker 7 MAP-2 using immunohistochemical staining (data not shown). By 72 hrs p.i. there was 8 immunostaining of rabies virus antigen in 78% of D29-infected cells (data not shown), while 9 staining was not observed in mock-infected cultures. At 24, 48, and 72 hrs p.i., 17%, 26%, and 10 28% of D29-infected cells expressed activated caspase 3, respectively (data not shown). 11
12
Dose-related effects of minocycline on viability of primary neuronal cultures 13
We initially evaluated viability of cortical neurons with minocycline over a concentration range 14 of 0 -200 nM. A concentration of 5 nM was selected for further studies because it showed only 15 small reductions in viability (5, 3 , and 0% at 24, 48, and 72 hrs p.i., respectively) on screening 16 toxicity studies in cultures (data not shown), and was similar to the concentration used by others 17 using embryonic neurons (9) . 18
19
D29 infection resulted in loss of viability in primary neuronal cultures 20
Neurons in the cortical ( Fig 1A) and hippocampal (Fig. 1B) cultures were infected with D29 or 21 mock-infected and analyzed for viability using trypan blue exclusion at days 1, 2, and 3 p.i. In three separate experiments there were small reductions in the viability of cultures with 5 nM 3 minocycline versus cultures without minocycline ( Fig. 1A and B ). In this system, 5 nM 4 minocycline did not affect the viral yield in cortical cultures (Fig. 1C ) and only demonstrated a 5 mild reduction in viral yield at 3 days p.i. in the hippocampal cultures (Fig. 1D ). 6 7 Clinical observations of mice 8
Forty-eight two-day-old mice were inoculated in the hindlimb thigh muscle with 100 focus-9
forming units of D29 and were given either minocycline (50 mg/kg/day) or vehicle (PBS) 10 administered once daily subcutaneously for a total of 18 treatments. Both cumulative clinical 11 neurological disease, including paresis and ataxia, and mortality (83% vs. 50% in vehicle-treated 12 controls) were significantly more marked in the minocycline-treated mice (log rank test, p=0.002 13 and p=0.003, respectively) (Fig. 2) . The larger repeat experiment (with 60 infected mice) 14 confirmed greater cumulative clinical neurological disease and mortality in the minocycline-15 treated mice (log rank test, p=0.006 and p=0.0002, respectively) (data not shown). Clinical 16 improvement of limb paresis occurred in a minority of mice (27%) in both treatment groups. 17
Hence, minocycline actually aggravated the neurological disease and increased the mortality rate 18 of the rabid mice in this model, rather than providing neuroprotection. 19 20
Rabies virus antigen distribution in mouse tissues 21
We compared the number of neurons expressing rabies virus antigen in the brains of 22 minocycline-and vehicle-treated moribund mice pooled from days 9 -21 p.i. (Fig. 3) . Generally, 23
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on September 28, 2016 by guest http://jvi.asm.org/ Downloaded from we found greater numbers of infected neurons in regional brain areas of the minocycline-treated 1 mice, which reached statistical significance in CA1 pyramidal neurons, indicating only modest 2 evidence of more widespread infection in the brains of minocycline-treated mice. In a separate 3 experiment mice were assessed on day 5, before the onset of clinical neurological disease, and 3 4 of 8 (38%) minocycline-treated mice and 2 of 8 (25%) vehicle-treated mice were found to have 5 infected neurons in the brain. On day 7, 3 of 4 (75%) minocycline-treated mice and 1 of 4 (25%) 6 vehicle-treated mice (with right hindlimb paresis) had infected neurons in the brain, 7 predominantly in the brainstem and cerebellum. 8 9
Neuronal apoptosis in mouse tissues 10
Minocycline-treated mice showed less neuronal apoptosis in the cerebellum and midbrain than 11 vehicle-treated mice, which achieved statistical significance in the midbrain (Mann-Whitney test, 12 p=0.012) (Fig. 4A ). 13
14
Immunohistochemical evaluation of activated caspase 3 and CD3 expression in mouse tissues 15
Immunohistochemical evaluation of the number of neurons expressing activated caspase 3 (13) , 16 which is a downstream executioner of the apoptotic process, also showed less expression in 17 minocycline-treated mice, and was highly significant in the midbrain (t test, p= 0.0008) ( Fig.  18 
4B). Immunohistochemical evaluation of inflammatory T cells using a CD3 marker (polyclonal 19
anti-human CD3, DakoCytomation, Glostrup, Denmark) showed less CD3-positive cells in 20 minocycline-treated mice than in vehicle-treated mice, with statistical significance in the 21 pons/medulla (t test, p=0.008) (Fig. 4C) . suppressed the viral load in the brain, and decreased the expression of inflammatory markers in 18 the brain (23). An effective neuroprotective agent would be an exciting advance in the therapy of 19 viral encephalitis in humans, and there is a temptation to use the drug empirically with the hope 20 that it might have a beneficial effect before the results of further studies in animals or humans 21 become available. This is especially true in rabies, which is almost always fatal. There is abundant evidence that rabies virus strains induce apoptosis of infected rodent 1 embryonic neurons in vitro (12, 19) . Furthermore, more attenuated rabies virus strains have a 2 greater capacity to induce neuronal apoptosis in vitro (12) . We have recently shown that the 3 highly attenuated D29 strain with a mutation at position 333 in the rabies virus glycoprotein also 4 has a greater capacity to induce neuronal apoptosis in vivo than the less attenuated L16 strain 5 from which it was derived. Minocycline did not produce neuroprotection of D29-infected 6 embryonic neurons in the present study. Although D29 infection is associated with increased 7 expression of activated caspase 3 in the embryonic neurons, there may also be D29-induced non-8 apoptotic mechanisms of cell death and caspase-independent mechanisms of apoptotic cell death, 9
as previously reported in rabies virus infection (15) , accounting for the loss of viability in these 10 primary neurons. 11
12
In the present neonatal mouse model, minocycline treatment of rabies virus-infected mice was 13 associated with more severe neurological disease and a higher mortality rate than treatment with 14 vehicle. The number of infected neurons in regional brain areas of moribund mice treated with 15 minocycline was greater than in those treated with vehicle, but this only reached statistical 16 significance in the CA1 region of the hippocampus. In mice assessed at earlier time points, 17
including before the onset of clinical neurological disease, there was a trend towards finding 18 more infected neurons in the brains of minocycline-than vehicle-treated mice. This suggests 19 mildly more efficient viral spread in the minocycline-treated mice, which could reflect effects on 20 host defenses, including both anti-inflammatory and anti-apoptotic effects. pathogenesis of the disease, rather than mainly a mechanism for host defense by inhibiting viral 5 spread (5, 12) . There were less CD3-positive cells in the brain parenchyma of minocycline-6 treated D29-infected mice than in vehicle-treated mice, which reached statistical significance in 7 the pons/medulla. This indicates an anti-inflammatory effect of minocycline, which may have 8 also affected other immune effectors and impaired the host's ability to control the infection, 9
resulting in aggravation of the rabies encephalomyelitis with a higher mortality rate. Both innate 10 and adaptive immunity are important for recovery from rabies virus infection (8) , and we feel 11 that the anti-inflammatory effects of minocycline were likely important in aggravating the rabies 12 encephalitis. 13
14
Minocycline has also been recognized to aggravate disease in animal models of 15 neurodegenerative diseases. In the 3-nitropropionic acid mouse model of Huntington's disease, 16 minocycline treatment was associated with a worse mean motor score, impaired general activity, 17 and significantly deteriorated performances on the rotarod, pole test, and beam-traversing tasks 18
and was associated with more severe neuronal cell loss in the dorsal striatum in comparison with 19 untreated mice (3). In minocycline-treated monkeys in a 1-methyl-4-phenyl-1,2,3,6-20 tetrahydropyridine (MPTP) model of Parkinson's disease, the same investigators also found 21 more severe clinical features of parkinsonism and greater loss of putaminal dopaminergic nerve 22 endings versus untreated animals (3) . Minocycline was also found to increase MPTP-induced 23
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on September 28, 2016 by guest http://jvi.asm.org/ Downloaded from damage to dopaminergic neurons in mice (20) . Although minocycline has been found to protect 1 against cerebral ischemia in a rat model of transient middle cerebral artery occlusion (22), the 2 opposite effect has been observed in a mouse model of hypoxic-ischemic brain injury (18) . 3 4 Given the present finding that minocycline therapy aggravated rabies encephalitis in an 5 experimental mouse model, we recommend that minocycline not be administered to human 6 patients with rabies and possibly other viral encephalitides on an empirical basis, because of its 7 potential ability to aggravate the disease. More studies are needed to understand the complex 8 effects of minocycline in different neurological diseases, including rabies and other viral 9 encephalitides. 10 11 Rabies. Academic Press, San Diego. midbrain, and pons/medulla of moribund mice that received daily treatment with vehicle (n=9) or 3 minocycline (n=12). Slides stained for caspase 3 or CD3 were masked and the numbers of 4 stained neurons and CD3-positive cells were counted by two independent observers in three 5 different fields of the same brain region using high power (40×) objective in areas with the most 6 marked staining. * represents statistical significance with p<0.05 using unpaired t-test and error 7 bars represent the standard error of the mean for comparisons of values for treatments with 8 vehicle vs. minocycline. 9
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